ClinicalTrials.gg
Not yet recruitingNCT06871787INOCAUpdated Nov 18, 2026

Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery

A Phase 4 interventional study of Indocyanine Green and Near-Infrared Fluorescence Imaging System in Gynecologic Cancers, Ovarian Cancer and Endometrial Cancers, sponsored by Istanbul University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Istanbul University · Phase 4, Interventional, and Diagnostic

How we know

Updated Nov 18, 2026First site in Turkey (Türkiye)No longer in Turkey+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Ovarian Neoplasms with a site in Turkey — 7 open to participants now, 15 under way, 8 of them phase 3. Ovarian Neoplasms · Turkey.

Planned enrollment
27th of 28
50 · median 382
Started
2027
the only one that year
Phase 4
Only one
of the 33
Primary completion
2029-06
later than 14 of 14 live
Registered
31st of 33
by date
Lead sponsor
2 of 33
Istanbul University

Among the 33 studies in Ovarian Neoplasms with a site in Turkey, this one is the 27th largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2027, is the only one in phase 4, reaches primary completion later than 14 of the 14 other live ones, and was the 31st registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

7 of the 33 studies in Ovarian Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Ovarian Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this study is to evaluate if indocyanine green (ICG) fluorescence imaging helps reduce complications in bowel surgery performed during gynecologic cancer operations.

The main question it aims to answer is: Does using ICG fluorescence imaging during bowel anastomosis reduce the rate of complications such as leaks, infections, and abscesses within 30 days after surgery? Participants are women aged 18 and older undergoing surgery for gynecologic cancers (such as ovarian, uterine, cervical, or vulvar cancer). During surgery, investigators will inject ICG intravenously, then use a special near-infrared camera to see how well blood flows at the anastomosis site. The investigators will then decide if the reconnection is good enough or needs adjustment.

Researchers will record any complications within the first 30 days after surgery to understand if this imaging method helps reduce surgical risks.

Read the detailed description

In gynecologic cancer surgeries, complete removal of the tumor often requires bowel resection (removal of part of the intestine). After resection, surgeons perform bowel anastomosis to restore gastrointestinal continuity. However, anastomosis can sometimes fail, leading to complications such as leaks, pelvic abscesses, or infections. Such complications significantly affect patient health, recovery, and outcomes.

Indocyanine green (ICG) is a dye approved by health authorities for clinical use. When injected into the bloodstream, it glows brightly under near-infrared (NIR) light, allowing investigators to visually assess blood flow in tissues during surgery. Good blood flow is critical for proper healing of the bowel reconnection.

This study aims to evaluate the effectiveness of using ICG-enhanced NIR fluorescence imaging specifically during gynecologic oncology surgeries involving bowel resections. After surgeons complete the anastomosis, ICG will be administered intravenously. Investigators will then examine the blood flow at the anastomosis site using a special near-infrared camera. If the blood flow appears insufficient, investigators may choose to revise the bowel connection during the same operation.

The study will include approximately 50 women undergoing surgery for gynecologic cancers such as ovarian, uterine, cervical, or vulvar cancer. The primary goal is to determine whether the use of this imaging technique reduces complications, especially within the first 30 days after surgery.

The results of this research could lead to safer surgical procedures, improved patient outcomes, and potentially influence clinical practice guidelines in gynecologic oncology.

03

Conditions studied

  • Gynecologic Cancers
  • Ovarian Cancer
  • Endometrial Cancers
  • Cervical Cancers
  • Vulvar Cancer
  • Anastomotic Leaks

Keywords

  • Indocyanine Green
  • Near-Infrared Imaging
  • Bowel Anastomosis
  • Gynecologic Oncology
  • Anastomotic Complications
  • Perfusion Assessment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 years or older.
  • Diagnosis of gynecologic cancer (ovarian, endometrial, cervical, vulvar) requiring surgical treatment.
  • Planned bowel resection and anastomosis during gynecologic oncology surgery.
  • Ability and willingness to provide .

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to indocyanine green (ICG).
  • Pregnancy or breastfeeding at the time of surgery.
  • Severe liver or kidney dysfunction limiting the use of ICG.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    ICG Fluorescence Imaging Group

    Women undergoing gynecologic oncology surgery with bowel resection and anastomosis. Anastomotic perfusion will be evaluated intraoperatively using indocyanine green (ICG) enhanced near-infrared fluorescence imaging.

    Drug: Indocyanine Green · Device: Near-Infrared Fluorescence Imaging System

Interventions

  • Indocyanine green (ICG), administered intravenously at a dose of 2.5 mg/ml, will be used during surgery to evaluate bowel anastomosis perfusion through near-infrared fluorescence imaging.

  • DeviceNear-Infrared Fluorescence Imaging System

    A near-infrared fluorescence imaging device will be used intraoperatively to visualize indocyanine green (ICG) fluorescence, assessing the perfusion of bowel anastomoses during gynecologic oncology surgery.

06

What researchers measure

Primary outcomes

  1. Rate of Anastomotic Complications within 30 Days After Surgery

    The primary outcome will be the incidence of anastomotic leaks, pelvic abscesses, and infections observed within 30 days following bowel anastomosis performed during gynecologic oncology surgery with indocyanine green-enhanced near-infrared fluorescence imaging.

    Time frame: 30 days after surgery

Secondary outcomes

  1. Number of Anastomoses Revised After Indocyanine Green Fluorescence Imaging

    The secondary outcome will evaluate how frequently the bowel anastomosis site was revised intraoperatively due to insufficient perfusion as detected by indocyanine green-enhanced near-infrared fluorescence imaging.

    Time frame: Intraoperative (During Surgery)

07

Study locations

1 site
  • Istanbul University, Istanbul Faculty of Medicine, Department of Gynecologic Oncology
    Istanbul, Istanbul 34093, Turkey (Türkiye)
    • Yagmur Minareci, Assist. Prof. · Contactdryagmurminareci@gmail.com · +905053574361
    • Atahan Toyran, Medical Doctor · Sub investigator
    • Yagmur Minareci, Assist. Prof. · Sub investigator
    • Samet Topuz, Prof. · Principal investigator
08

References and documents

Publications

  • Emile SH, Khan SM, Wexner SD. Impact of change in the surgical plan based on indocyanine green fluorescence angiography on the rates of colorectal anastomotic leak: a systematic review and meta-analysis. Surg Endosc. 2022 Apr;36(4):2245-2257. doi: 10.1007/s00464-021-08973-2. Epub 2022 Jan 13. PubMed 35024926 ↗
  • Chan DKH, Lee SKF, Ang JJ. Indocyanine green fluorescence angiography decreases the risk of colorectal anastomotic leakage: Systematic review and meta-analysis. Surgery. 2020 Dec;168(6):1128-1137. doi: 10.1016/j.surg.2020.08.024. Epub 2020 Oct 1. PubMed 33010938 ↗
  • Parthasarathy M, Greensmith M, Bowers D, Groot-Wassink T. Risk factors for anastomotic leakage after colorectal resection: a retrospective analysis of 17 518 patients. Colorectal Dis. 2017 Mar;19(3):288-298. doi: 10.1111/codi.13476. PubMed 27474844 ↗
  • BRUNSCHWIG A. Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948 Jul;1(2):177-83. doi: 10.1002/1097-0142(194807)1:23.0.co;2-a. No abstract available. PubMed 18875031 ↗
  • Grimm C, Harter P, Alesina PF, Prader S, Schneider S, Ataseven B, Meier B, Brunkhorst V, Hinrichs J, Kurzeder C, Heitz F, Kahl A, Traut A, Groeben HT, Walz M, du Bois A. The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery. Gynecol Oncol. 2017 Sep;146(3):498-503. doi: 10.1016/j.ygyno.2017.06.007. Epub 2017 Jun 10. PubMed 28610745 ↗
  • Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424. PubMed 30811909 ↗
  • Morales-Conde S, Alarcon I, Yang T, Licardie E, Camacho V, Aguilar Del Castillo F, Balla A. Fluorescence angiography with indocyanine green (ICG) to evaluate anastomosis in colorectal surgery: where does it have more value? Surg Endosc. 2020 Sep;34(9):3897-3907. doi: 10.1007/s00464-019-07159-1. Epub 2019 Oct 4. PubMed 31586247 ↗

Individual participant data

Plan to share: Undecided — A decision regarding individual participant data (IPD) sharing has not yet been made. Data sharing will be considered upon completion of the study and publication of results.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jun 2027; primary completion for Jun 2029, 24 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Sep 2025 → Jun 2027, primary completion Sep 2027 → Jun 2029 and completion Dec 2027 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2025
First posted
Mar 12, 2025
StartEst.
Jun 2027was Sep 2025
Primary completionEst.
Jun 2029was Sep 2027
CompletionEst.
Jun 2029was Dec 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
Show site
  • Istanbul University, Istanbul Faculty of Medicine, Department of Gynecologic Oncology · Istanbul, Turkey (Türkiye)
Show 1 removed
  • Istanbul University, Istanbul Faculty of Medicine, Department of Gynecologic Oncology · Istanbul, Turkey
Nov 18, 2026
Start date
Sep 1, 2025→Jun 2027
Nov 18, 2026
Primary completion
Sep 1, 2027→Jun 2029
Nov 18, 2026
Study completion
Dec 30, 2027→Jun 2029
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
    Show site
    • Istanbul University, Istanbul Faculty of Medicine, Department of Gynecologic Oncology · Istanbul, Turkey (Türkiye)
    Show 1 removed
    • Istanbul University, Istanbul Faculty of Medicine, Department of Gynecologic Oncology · Istanbul, Turkey
    Start date Sep 1, 2025→Jun 2027
    Primary completion Sep 1, 2027→Jun 2029
    Study completion Dec 30, 2027→Jun 2029
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06871787
Responsible party
Atahan Toyran (Principal Investigator, Istanbul University) — Principal investigator
First posted
Mar 12, 2025
Start date
Jun 2027 (estimated)
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Atahan Toyran, Medical Doctor
Contact
atahan.toyran@istanbul.edu.tr
+905057146233
Yagmur Minareci, Assist. Prof.
Contact
dryagmurminareci@gmail.com
+905053574361
Samet Topuz, Prof.
study chair · Istanbul University
Yagmur Minareci, Assist. Prof.
study director · Istanbul University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indocyanine Green

Start the discussion